Francis Cano Purchases 16,667 Shares of Dynavax Technologies Co. (NASDAQ:DVAX) Stock

Dynavax Technologies Co. (NASDAQ:DVAX) Director Francis Cano acquired 16,667 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average cost of $3.00 per share, for a total transaction of $50,001.00. Following the completion of the transaction, the director now directly owns 118,484 shares in the company, valued at approximately $355,452. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

DVAX stock traded down $0.02 during midday trading on Monday, hitting $3.36. The company’s stock had a trading volume of 2,306,404 shares, compared to its average volume of 1,310,589. The company has a quick ratio of 4.61, a current ratio of 4.30 and a debt-to-equity ratio of 19.95. Dynavax Technologies Co. has a twelve month low of $2.60 and a twelve month high of $14.35. The business has a fifty day moving average price of $3.49. The firm has a market cap of $218.40 million, a PE ratio of -1.32 and a beta of 0.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.03). Dynavax Technologies had a negative net margin of 781.10% and a negative return on equity of 304.71%. The business had revenue of $8.30 million during the quarter, compared to analyst estimates of $8.24 million. During the same quarter in the previous year, the firm posted ($0.63) earnings per share. The firm’s quarterly revenue was up 564.0% on a year-over-year basis. As a group, equities research analysts forecast that Dynavax Technologies Co. will post -2.13 earnings per share for the current fiscal year.

Several research firms recently commented on DVAX. Cowen reaffirmed a “buy” rating on shares of Dynavax Technologies in a research report on Monday, June 3rd. Zacks Investment Research cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a research report on Friday, June 21st. BidaskClub raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, June 29th. Finally, ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Dynavax Technologies has a consensus rating of “Buy” and an average price target of $16.81.

Hedge funds have recently modified their holdings of the business. Rhenman & Partners Asset Management AB lifted its position in shares of Dynavax Technologies by 333.1% during the second quarter. Rhenman & Partners Asset Management AB now owns 1,234,335 shares of the biopharmaceutical company’s stock valued at $4,925,000 after purchasing an additional 949,335 shares in the last quarter. Millennium Management LLC increased its holdings in Dynavax Technologies by 513.7% in the 4th quarter. Millennium Management LLC now owns 614,930 shares of the biopharmaceutical company’s stock worth $5,627,000 after acquiring an additional 514,736 shares in the last quarter. C WorldWide Group Holding A S increased its holdings in Dynavax Technologies by 100.7% in the 2nd quarter. C WorldWide Group Holding A S now owns 996,412 shares of the biopharmaceutical company’s stock worth $3,976,000 after acquiring an additional 500,000 shares in the last quarter. Chicago Capital LLC increased its holdings in Dynavax Technologies by 18.8% in the 1st quarter. Chicago Capital LLC now owns 2,544,142 shares of the biopharmaceutical company’s stock worth $18,598,000 after acquiring an additional 402,411 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in Dynavax Technologies in the 1st quarter worth approximately $1,468,000. Hedge funds and other institutional investors own 83.32% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Read More: How to Invest in an Index Fund

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.